FORMATION OF ANTI-INFECTIOUS AND POST-VACCINATION ANTI-SARS-COV-2 HUMORAL IMMUNITY IN MEDICAL WORKERS OF THE PERINATAL CENTER


Cite item

Abstract

In the context of the global spread of the new coronavirus infection, studies aimed at investigating formation of anti-infectious and post-vaccination immunity are of special importance, which is necessary to prevent and reduce morbidity and mortality due to SARS-CoV-2 infection.

Purpose: to assess anti-infectious immunity against SARS-COV-2 in various forms of the disease and development of post-vaccination humoral reactions in medical workers of the perinatal center. Materials and methods. A study of blood serum was carried out to assess SARS-CoV-2-specific IgM and IgG antibodies in 119 medical workers recovered after COVID-19, divided into groups based on the disease severity (mild, moderate and asymptomatic), as well as in 62 vaccinated employees, divided into groups according to age. Semi-quantitative measurement of virus-specific antibodies was carried out by ELISA with test systems "SARS-COV-2-IgG-ELISA-BEST" and "SARS-COV-2-IgM-ELISA-BEST".

Statistical processing of the research results was carried out using Microsoft Excel 2010 and Statistica 6. Quantitative characteristics were presented as median (ME), lower and upper quartiles (LQ1-UQ3); qualitative parameters – as absolute value and relative number (%). Difference between groups was analyzed by using the χ2 test (qualitative) and the Mann-Whitney U-test (quantitative).

Results. The results of the study showed that the majority of employees with a moderate-severe form of SARS-COV-2 had a high level of IgG (PR - a positivity rate of more than 9.0 arbitrary units) 9 months after the disease compared to those who suffered from mild or asymptomatic (83.3% versus 25.8% and 13.3%, p <0.017) infection. The duration of IgG circulation after former illness had no relation to its severity and patient age. The effectiveness of the primary vaccination "Sputnik V" and revaccination with "Sputnik Light" and "KoviVak" was 100% after inoculating the vaccine second component. The lowest level of antibodies after the first vaccination is recorded in persons over 60 years old (1.48 (1.12-3.25 versus PR = 8.48 (5.78-10.11) and 9.27 (5.84-10, 31) arbitrary units, p <0.017)), in comparison with young and middle-age subjects. The speed SARS-COV-2 elimination of IgG at 6, 9 or more months after vaccination depends on relevant initial peak antibody concentration. Subjects who were initially vaccinated with the KoviVac vaccine, IgG was not detected 2 months after vaccination. The protective effect of "Sputnik V", "Sputnik Light", "KoviVac" after re-infection with SARS-COV-2 averages 71.2%. Conclusion. Thus, the results obtained on assessing anti-infectious and post-vaccination immunity against SARS-CoV-2 emphasize the need for further studies on a larger patient cohort, especially in those with asymptomatic infection as well as the elderly subjects.

About the authors

G. Chistyakova

ФГБУ "«Уральский научно-исследовательский институт материнства и младенчества» Министерства здравоохранения Российской Федерации

Email: chistyakovagn@niiomm.ru
ORCID iD: 0000-0002-0852-6766

Отделения иммунологии, микробиологии, патоморфологии и цитодиагностики,  руководитель 

Russian Federation

G. Malgina

ФГБУ "«Уральский научно-исследовательский институт материнства и младенчества» Министерства здравоохранения Российской Федерации

Email: galinamalgina@mail.ru
ORCID iD: 0000-0002-5500-6296

ФГБУ «Уральский научно-исследовательский институт материнства и младенчества» Минздрава России, директор

Russian Federation

A. Ustyuzhanin

ФГБУ "«Уральский научно-исследовательский институт материнства и младенчества» Министерства здравоохранения Российской Федерации

Author for correspondence.
Email: RemizovaII@yandex.ru
ORCID iD: 0000-0002-4238-4642

Отделение иммунологии, микробиологии, патоморфологии и цитодиагностики, старший научный сотрудник, SPIN 7222-4271

Russian Federation

I. Remizova

ФГБУ "«Уральский научно-исследовательский институт материнства и младенчества» Министерства здравоохранения Российской Федерации

Email: ust103@yandex.ru
ORCID iD: 0000-0001-8521-7652

Отделение иммунологии, микробиологии, патоморфологии и цитодиагностики, старший научный сотрудник, SPIN 8861-0584

Russian Federation

References

  1. Алексанин С.С., Алхутова Н.А., Ковязина Н.А., Рыбников В.Ю. Динамика уровня антител класса G к SARS-CoV-2 после перенесенной новой коронавирусной инфекции COVID-19 // Медицинский алфавит. 2021. Т. 1, № 30. С. 7-11.
  2. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 13 (14.10.2021).
  3. Гавриш В.С., Шаркова В.Е., Полынцев Д.Г., Оленькова О.М. , Бейкин Я.Б. , Старокорова Е.Ю. , Нечаева В.В. , Зыкова Т.М. , Ламонова Н.Ю. Сравнительное исследование поствакцинального иммунитета к вирусу SARS-CoV-2 методами ИФА и реакции нейтрализации вируса // Справочник заведующего КДЛ. 2021. № 9, С. 46-56.
  4. Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Башкетова Н.С., Фридман Р.К., Лялина Л.В., Смирнов В.С., Чхинджерия И.Г., Гречанинова Т.А., Агапов К.А., Арсентьева Н.А., Баженова Н.А., Бацунов О.К., Данилова Е.М., Зуева Е.В., Комкова Д.В., Кузнецова Р.Н., Любимова Н.Е. Популяционный иммунитет к вирусу SARS-CoV-2 среди населения Санкт-Петербурга в активную фазу эпидемиии COVID-19. Проблемы особо опасных инфекций. 2020; 3: 124-130.
  5. Платонова Т. А., Голубкова А. А., Карбовничая Е. А., Смирнова С.С. Особенности формирования гуморального иммунитета у лиц с различными клиническими проявлениями COVID-19. Эпидемиология и Вакцинопрофилактика. 2021. Т. 20, № 1, С. 20–25.
  6. Решетникова И.Д., Тюрин Ю.А., Агафонова Е.В., Куликов С.Н., Гилязутдинова Г.Ф., Лопушов Д.В., Шайхразиева Н.Д., Исаева Г.Ш., Зиатдинов В.Б. Изучение особенностей гуморального иммунного ответа к новой коронавирусной инфекции covid-19 среди медицинских работников // Инфекция и иммунитет. 2021. Т.11, № 8. С. 934–942.
  7. Kirkcaldy R.D., King B.A., Brooks J.T. COVID-19 and post-infectious immunity: limited evidence, many unresolved questions. JAMA, 2020, vol. 323, no 22, pp. 2245-2246.
  8. Lin Y., Zhao Z., Zheng J., Liu J., Huang A. Realization of humoral immunity against SARS-CoV-2 infections. Fundamental ResearchVolume 1, Issue 2, March 2021, pp. 186-188.
  9. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., Botikov A.G., Izhaeva F.M., Popova O., Ozharovskaya T.A., Esmagambetov I.B., Favorskaya I.A., Zrelkin D.I., Voronina D.V., Shcherbinin D.N., et al. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet, 2021, vol. 397, no 10275, pp. 671-681.
  10. Poland G.A., Ovsyannikova I.G., Kennedy R.B., SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet, 2020, no 396, pp. 1595–1606.
  11. Reifer J., Hayum N., Heszkel B., Klagsbald I., Streva V.A. SARS-CoV-2 IgG antibody responses in New York City. Diagn Microbiol Infect Dis. 2020, vol. 98, no 3, 115128.
  12. Sheikh A., McMenamin J., Taylor B., Robertson S., Public Health Scotland and EAVE II staff. SARS-CoV-2 Delta VOC in Scotland: demographics, hospitalization risk and vaccine effectiveness. Lancet, 2021, vol. 397 no 10293, pp. 2461-2462.
  13. Turner J.S., Kim W., Kalaidina E., Goss C.W., Rauseo A.M., Schmitz A.J., Hansen L., Haile A., Klebert M.K., Pusic I., O’Halloran J.A., Presti R.M., Ellebed A.H. SARS-CoV-2 infection induces long-lived plasma cells in the bone marrow in humans. Nature. 2021, vol. 595, pp. 421-425.
  14. Tut G., Lancaster T., Krutikov M., Sylla P., Bone D., Kaur N., Spalkova E., Bentley C., Amin U., Jadir A.T., Hulme S., Butler M.S., Ayodele M., Bruton R., Shrotri M., Azmi B., Fuller C., Irwin-Singer A., Hayward A. et al. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study. The Lancet Healthy Longevity. 2021, Vol. 2, Issue 9, pp. e544-e553.
  15. Wei J., Matthews P.C., Stoesser N., Maddox T., Lorenzi L., Studley R., Bell J.I., Newton J.N., Farrar J., Diamond I., Rourke E., Howarth A., Marsden B.D., Hoosdally S., Jones E.Y., Stuart D.I., Crook D.W., Peto T.E.A., K.B. Pouwels et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. National Commune. 2021, vol, 12, no 6250.

Supplementary files

There are no supplementary files to display.


Copyright (c) Chistyakova G., Malgina G., Ustyuzhanin A., Remizova I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies